ProCE Banner Activity

How to Implement Earlier Hepatitis B Treatment

Podcast Episodes

Listen as Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, review strategies for more expansive HBV treatment while considering adverse events, cost-effectiveness, and patient perspectives. 

Released: March 26, 2024

Share

Faculty

Jacki Chen

Jacki Chen, PhD

Patient Advocate

Tatyana Kushner

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Gastroenterology/ Hepatology
Department of Obstetrics & Gynecology
Weill Cornell Medicine
New York, New York

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Mark S. Sulkowski

Mark S. Sulkowski, MD, FIDSA, FAASLD

Professor of Medicine
Director, Division of Infectious Diseases Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC, in partnership with Hepatitis B Foundation

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

Hepatitis B Foundation

ProCE Banner

Disclosure

Primary Author

Jacki Chen, PhD

Patient Advocate

Jacki Chen, PhD: consultant/advisor/speaker: GlaxoSmithKline.

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Gastroenterology/ Hepatology
Department of Obstetrics & Gynecology
Weill Cornell Medicine
New York, New York

Tatyana Kushner, MD, MSCE: consultant/advisor/speaker: AbbVie, Aligos, GlaxoSmithKline; researcher: Gilead.

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD: consultant/advisor: Aligos, Drug Farm, Eiger, Galapagos, Gilead, HEPQuant, Inventiva, Mallinckrodt, Mirum, Surrozen; researcher: Altimmune, Eiger, Gilead, Novo Nordisk; individual publicly traded stocks/stock options: Durect.

Mark S. Sulkowski, MD, FIDSA, FAASLD

Professor of Medicine
Director, Division of Infectious Diseases Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark S. Sulkowski, MD, FIDSA, FAASLD: consultant/advisor/speaker: AbbVie, Gilead, GlaxoSmithKline; data and safety monitoring board: Gilead.